{"lastModified":"2024-07-05T22:00:35","links":[{"href":"https://sejm.gov.pl/sejm10.nsf/interpelacja.xsp?typ=int&nr=2920","rel":"web-description"},{"href":"https://sejm.gov.pl/sejm10.nsf/interpelacjaTresc.xsp?key=D65AMK","rel":"web-body"},{"href":"https://api.sejm.gov.pl/sejm/term10/interpellations/2920/body","rel":"body"}],"num":2920,"receiptDate":"2024-05-22","term":10,"title":"Interpelacja w sprawie stosowania w Polsce leków przeciwpsychotycznych o przedłużonym uwalnianiu (np. Abilify Maintena)","answerDelayedDays":0,"from":["417"],"recipientDetails":[{"answerDelayedDays":0,"name":"minister zdrowia","sent":"2024-06-11"}],"replies":[{"attachments":[{"URL":"https://api.sejm.gov.pl/sejm/term10/interpellations/attachment/ATTD6VHXH/i02920-o1.pdf","lastModified":"2024-07-05T22:00:35","name":"i02920-o1.pdf"}],"from":"Podsekretarz stanu Marek Kos","key":"D6VHXH","lastModified":"2024-07-05T22:00:35","links":[{"href":"https://sejm.gov.pl/sejm10.nsf/interpelacjaTresc.xsp?key=D6VHXH","rel":"web-body"},{"href":"https://api.sejm.gov.pl/sejm/term10/interpellations/2920/reply/D6VHXH/body","rel":"body"}],"onlyAttachment":true,"prolongation":false,"receiptDate":"2024-06-30"}],"sentDate":"2024-06-11","to":["minister zdrowia"]}